The rotation into value, financials, and industrials is accelerating faster than most investors realize.
Big Pharma Has $1.3 Trillion to Spend. The Clock Is Running.
A patent cliff with a known deadline is forcing the largest acquisition wave in biopharma history.
Tesla Delivered 480,126 Cars. The Stock Dropped 7% Anyway.
The delivery beat was never really the question. July 22 is.
Bending Spoons Is Now Public. The Story Has 1,000 Chapters Left.
An Italian software roll-up just had one of the year's best IPO debuts.
Vertiv Is Up 73% in 2026. Now Comes the Hard Part.
Q2 earnings are *estimated* for July 29. The backlog is massive. The valuation is not cheap.
Meta Just Became Its Own Competition
A $125 billion AI infrastructure budget is about to flip from cost center to revenue engine.
NVDA Is Down 17% From Its High. The August 26 Earnings Date Is the Only Number That Matters.
Record revenue, a $91B guide, and a stock that won't hold gains. Here is where the trade actually lives.
Rocket Lab Just Changed the Space Economy Overnight
An $8 billion Iridium deal turns RKLB into a vertically integrated satellite powerhouse.
Nike Reports Tomorrow. The Number Everyone Will Ignore Is the One That Matters.
With Q4 earnings due Tuesday, the real debate isn't the revenue miss — it's whether gross margin can hold.
Exxon and Chevron Had a Monster Year. Then General License X Happened.
A Treasury authorization just unlocked Iranian crude, and energy's biggest 2026 winners are paying for it now.